8-K: NextCure Prioritizes LNCB74, Reports Q3 2024 Financials, and Seeks Partnerships for Other Programs

NextCure is focusing its resources on the development of LNCB74, a B7-H4 ADC, with a planned IND submission by year-end, while seeking partners for other programs.

Summary

• NextCure announced its third-quarter 2024 financial results and provided a business update, highlighting a strategic shift to prioritize the development of LNCB74, a B7-H4 antibody-drug conjugate (ADC).
• The company plans to submit an Investigational New Drug (IND) application for LNCB74 by the end of 2024 and advance it into Phase 1 trials shortly after receiving FDA approval.
• While the NC410 combination therapy showed encouraging Phase 1b clinical activity in ovarian and colorectal cancer patients, NextCure intends to conclude the current trial and seek a partner to further develop the program.
• As of September 30, 2024, NextCure had $75.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2026.
• Research and development expenses for the quarter were $8.8 million, down from $11.0 million in the same period last year, while general and administrative expenses decreased to $3.7 million from $4.6 million.
• The net loss for the quarter was $11.5 million, an improvement from the $14.3 million loss in the third quarter of 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the focus on LNCB74 and the extended cash runway are positive, the need to seek partners for other programs and the modest clinical results for NC410 temper the overall sentiment.

Positives

• The company has a clear focus on advancing LNCB74, a promising ADC candidate.
• NextCure has sufficient cash reserves to fund operations into the second half of 2026.
• The company is actively seeking partnerships to advance other programs, potentially reducing financial burden.
• The net loss for the quarter decreased compared to the same period last year.
• The company is presenting preclinical data at a major industry conference.

Negatives

• The company is concluding the current trial for NC410 and seeking a partner, indicating a potential delay in its development.
• The company is seeking external funding for multiple programs, which may be challenging to secure.
• The company has a history of significant losses.
• The company is dependent on key personnel.

Risks

• Positive preclinical results may not translate to successful clinical trials.
• The company has a limited operating history and no approved products.
• NextCure may not be able to secure additional financing on acceptable terms.
• Clinical development, marketing approval, and commercialization of therapies are subject to significant risks.
• The company is dependent on key personnel.

Future Outlook

NextCure expects its current financial resources to fund operations into the second half of 2026 and plans to advance LNCB74 into Phase 1 trials after IND submission. The company will seek partners or third-party financing for other programs.

Management Comments

• Michael Richman, NextCure's president and CEO, stated that the November SITC presentation of LNCB74 preclinical data will highlight the differentiation of their B7-H4 ADC.
• Michael Richman also mentioned the plan to file an IND in the fourth quarter of this year and advance into Phase 1, shortly following receipt of an FDA safe-to-proceed letter.

Industry Context

The focus on antibody-drug conjugates (ADCs) like LNCB74 aligns with the growing interest in targeted cancer therapies. The decision to seek partners for other programs reflects a common strategy in the biotech industry to manage risk and resources.

Comparison to Industry Standards

• The 25% response rate in ICI-naive ovarian cancer patients for NC410 is a modest result compared to some other targeted therapies in development, but it is important to note that this is a Phase 1b trial.
• The 8.3% response rate in a subset of colorectal cancer patients is also modest, but the disease control rate of 47% and median duration of response of 15.2 months are more encouraging.
• The company's cash runway into the second half of 2026 is relatively good compared to many other clinical-stage biotechs, providing some financial stability.
• The decision to seek partners for NC410 and other programs is a common strategy for companies with limited resources, similar to other companies such as Xencor and MacroGenics who have partnered out assets to larger pharmaceutical companies.

Stakeholder Impact

• Shareholders may view the focus on LNCB74 as a positive strategic move, but may be concerned about the need for external funding for other programs.
• Employees may experience changes in project priorities and resource allocation.
• Potential partners may be interested in the NC410, NC181, and NC605 programs.
• Customers (patients) may benefit from the development of new therapies.

Next Steps

• NextCure plans to present preclinical data for LNCB74 and NC410 at the SITC annual meeting in November.
• The company intends to submit an IND application for LNCB74 by the end of 2024.
• NextCure will seek partners or third-party financing to advance NC410, NC181, and NC605 programs.

Key Dates

Keywords

LNCB74, B7-H4 ADC, NC410, Antibody-drug conjugate, Immunotherapy, Oncology, Clinical trials, Partnership, Biopharmaceutical, Financial results